Robert B. Jones - 03 Jan 2023 Form 4 Insider Report for ACURA PHARMACEUTICALS, INC

Role
President & CEO
Signature
/s/ Robert B. Jones
Issuer symbol
N/A
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
05 Jan 2023, 15:09:23 UTC
Previous filing
05 Aug 2022
Next filing
20 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACUR Common Stock Options Exercise +50,000 +9% 603,555 03 Jan 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACUR Restricted Stock Unit (2017 Plan) Options Exercise +50,000 40,000 03 Jan 2023 Common Stock 50,000 $0.0100 Direct F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents exchange of restricted stock units.
F2 Par value of $.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for stock.
F3 Does not include Restricted Stock Units.
F4 Not Applicable.
F5 150,000 Restricted Stock Units were granted on December 11, 2018 and were 100% vested on December 11, 2019. Distributions in respect of this vested Restricted Stock Units will be made in three equal installments in each of 2021, 2022, and 2023 or earlier upon a qualifying change of control which also meets certain criteria of Section 409A of the Internal Revenue Code.